SWOG clinical trial number
CTSU/C10603

Phase III Randomized Study of Induction Therapy Comprising Daunorubicin Hydrochloride and Cytarabine With or Without Midostaurin Followed by Consolidation Therapy Comprising High-Dose Cytarabine and Midostaurin Followed by Continuation Therapy Comprising Midostaurin Alone in Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Closed
Phase
Published
Abbreviated Title
Phase III Flt3+ AML Daunorubicin+AraC +/- Midostaurin Induction, AraC/Midostaurin Consolidation, Midostaurin Continuation
Activated
02/01/2009
Closed
10/15/2011
Participants
CTSU

Research committees

Leukemia